Business

Dr. Scott Gottlieb believes omicron BA.2 sub-variant is unlikely to cause a ‘national wave’ in the US

Dr. Scott Gottlieb told CNBC on Tuesday that the U.S. will avoid a “national wave” associated with the more contagious omicron BA.2 this spring.

However, the former Food and Drug Administration commissioner told the Squawk Box that in some parts of the country he believes cases are “dramatically” declining. Considering addiction in home trials now, he estimated that in the Northeast, one in seven or one in eight infections actually appears in official case counts.

“I think we’re more involved than we think,” Gottlieb said, pointing to Germany and the UK, where cases are starting to drop rapidly from the last peak associated with BA.2.

In the US, BA.2 is the main version of Covid, according to the Centers for Disease Control and Prevention. Some hope that in two weeks ’time, the previous version of omicron could be relocated, which increased the number of cases and hospitalizations at the end of last year and in 2022.

Covid infections and hospitalizations have dropped more than 90% in the omicron wave from January highs.

“It’s probably not going to be a national wave of infection,” from BA.2, announced Gottlieb, who led the FDA in the Trump administration from 2017 to 2019 and now serves on the board of manufacturer Pfizer Covid. “It will probably focus on the Northeast, perhaps in Florida. I think by the time it starts to spread nationally, we’ll be entering the summer already, which will provide seasonal protection.”

The picture may change in the fall for a number of reasons, Gottliebe said. “We’re going to have to deal with that in the fall,” he said. “It simply came to our notice then [BA.2] it is still the main variant of the country that has not been introduced right now, as it will begin to spread in the fall as people’s immunity begins to weaken, moving away from their previous vaccine and omicron infection. . “

Outreach: Dr. Scott Gottlieb is a CNBC contributor and a member of the boards of Pfizer, Tempus’s genetic testing start-up company, Aetion, and biotechnology. Illuminate. He is also the co-chair Norwegian Cruise Line Holdings‘and Royal Caribbean“Healthy Sailing Panel”.

Dr. Scott Gottlieb believes omicron BA.2 sub-variant is unlikely to cause a ‘national wave’ in the US

Source link Dr. Scott Gottlieb believes omicron BA.2 sub-variant is unlikely to cause a ‘national wave’ in the US

Back to top button